Micropulse diode TSCPC consistently lowers IOP

Article

Micropulse diode transscleral cyclophotocoagulation (TSCPC) lowers IOP consistently, predictably, and with minimal ocular complications, according to a recently published study.

Micropulse diode transscleral cyclophotocoagulation (TSCPC) lowers IOP consistently, predictably, and with minimal ocular complications, according to a study recently published in Clinical & Experimental Ophthalmology.

In a randomized, comparative, explorative study, researchers from London and Singapore randomly assigned 48 hospital patients who had refractory, end-stage glaucoma to undergo diode TSCPC in micropulse mode or in continuous mode. Researchers monitored IOP, visual acuity (VA), number of medications taken and whether re-treatment was necessary. Complications included a decline in VA, prolonged anterior chamber inflammation, phthisis bulbi, scleral thinning and ocular pain.

After 12 months, a primary outcome - IOP between 6 and 21 mmHg - was noted in 75% of study participants whose cyclophotocoagulation was performed in micropulse mode and 29% who received continuous mode. Another primary outcome was a minimum 30% reduction with or without anti-glaucoma medications after 18 months. At this point in the study, this primary outcome was seen in 52% of micropulse mode patients and 30% of continuous mode participants, respectively.

Mean IOP was reduced by 45% in both groups from a baseline of 36.5 mmHg and 35.0 mmHg after a range of 16 to 19 months of follow-up. The investigators did not see significant difference in the re-treatment rates or in the number of IOP-lowering medications taken. The ocular complication rate was higher in the eyes treated in continuous wave mode.

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.